Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma

The molecular pathways which promote lung cancer cell features have been broadly explored, leading to significant improvement in prognostic and diagnostic strategies. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) dramatically altered the treatment approach for patients with metastatic non-small (NSCLC). Latest investigations by using next-generation sequencing (NGS) shown that other oncogenic driver mutations, believed mutually exclusive decades, could coexist EGFR-mutated NSCLC patients. However, exact clinical pathological role of concomitant genomic aberrations needs be investigated. In this systematic review, we aimed summarize recent data on concurrent alterations, specifically evaluating characteristics, significance, their potential impact approach.